哌拉西林/舒巴坦治疗呼吸机相关性肺炎的临床疗效和微生物学评价  

Assessing the effects of piperacillin/sulbactam in the treatment of ventilator-associated pneumonia

作　　者：王满[1] 许力军[1] 关英慧[1] 金香[1] 张洪泉[1] 

机构地区：[1]吉林大学第一临床医院呼吸科,长春130021

出　　处：《中国临床药理学杂志》2011年第1期3-6,共4页The Chinese Journal of Clinical Pharmacology

摘　　要：目的研究哌拉西林钠(青霉素类抗生素)/舒巴坦钠(β内酰胺酶抑制剂)治疗呼吸机相关性肺炎(VAP)的临床疗效和微生物学评价。方法用前瞻性队列分析本院2009年9月-2010年9月应用哌拉西林/舒巴坦和哌拉西林/他唑巴坦治疗呼吸机相关性肺炎患者;共入组患者106例,其中哌拉西林钠/舒巴坦钠治疗组50例,哌拉西林/他唑巴坦治疗治疗组56例;比较2组的临床疗效和细菌清除率。结果哌拉西林/舒巴坦组的痊愈率为46.0%(23/50),显效率30.0%(15/50),临床有效率为76.0%(38/50);哌拉西林/他唑巴坦组的痊愈率为48.2%(27/56),显效率为26.8%(15/56),临床有效率为76.8%(43/56)。结论在治疗VAP中,哌拉西林/舒巴坦和哌拉西林/他唑巴坦的临床疗效和细菌清除率相似;哌拉西林/舒巴坦对VAP常见分离菌有良好的体外抗菌活性。Objective To evaluate the reliability of piperacillin/sulbactam on the patients with ventilator - associated pneumonia （VAP） with clinical efficacy and bacterial clearance rate. Methods A total of 106 patients with VAP were enrolled into this clinical study, including 50 cases in piperacillin/sulbactam group （PSB group） and 56 cases in piperacillin/tazobactam group （PTZ group）. The clinical efficacy and bacterial clearance rate of piperacillin/sulbactam and piperaeillin/tazobactam in the treatment of VAP were prospectively analyzed during the period of Oct 2009 to Oct 2010. Results The cure and effective rates were 46. 0% and 76.0% in the PSB group and 48.2% and 76.8% in the PTZ group, respectively. Conclusion Piperacillin/sulbactam is as effective as piperacillin/tazobactam for the treatment of VAP. Piperacillin/sulbactam exhibits good activity again common strains isolated from VAP.

关 键 词：哌拉西林/舒巴坦 呼吸机相关性肺炎 细菌清除率 

分 类 号：R978.11[医药卫生—药品] R515[医药卫生—药学]